Highlights
- Clinuvel Pharmaceuticals (ASX:CUV) recorded AUD 101.2 million FY26 revenue.
- Net profit was AUD 33.9 million for FY26.
- Cash reserves reached AUD 252.1 million at year-end.
- SCENESSE is approved in several markets for adult EPP patients.
Clinuvel Pharmaceuticals develops and commercialises treatments for genetic, metabolic and dermatological disorders, including its SCENESSE therapy for erythropoietic protoporphyria. On November 17, 2026, Clinuvel shares (ASX:CUV) traded at AUD 7.44, down 1.98% during the session. Its FY26 results showed lower annual Revenue and profit than FY25, alongside an increase in cash reserves and continuing work across its therapeutic pipeline.
SCENESSE and the Research Portfolio
Clinuvel’s principal commercial product, SCENESSE, contains afamelanotide and is used for preventing phototoxic reactions in adults with erythropoietic protoporphyria, a rare inherited condition. The company lists approved commercial markets including Europe, the United States, Canada, Israel and Australia. Clinuvel (ASX:CUV) also develops programmes involving melanocortin peptides and photomedicine, with work in dermatological and pigment-related conditions.
Commercial medicine Supply requires regulatory authorisations, physician engagement, patient access arrangements and specialised distribution. Research programmes have different timelines and risks from established product sales, particularly while clinical evidence is being generated. The company’s Business therefore includes both recurring commercial activity and expenditure on development work that may not produce near-term revenue.
2026 Reporting and Programme Activity
Clinuvel (ASX:CUV) published its Appendix 4E and FY2026 Annual Report on August 27, 2026. The company also held a results webinar the following day to discuss financial performance and its expansion and product-development plans. Its investor communications identify work spanning photomedicine and vitiligo alongside the approved EPP indication.
The group has discussed geographic and therapeutic expansion, but regulatory approval for one indication or country does not establish approval elsewhere. Accordingly, the status of individual research programmes and commercial jurisdictions matters when evaluating operational progress. The company also held its 2026 Annual General Meeting in November, giving shareholders a further company forum following the annual results.
FY26 Revenue, Profit and Balance Sheet
Clinuvel (ASX:CUV) reported FY26 revenue of AUD 101.2 million, compared with AUD 105.3 million in FY25. Net profit declined to AUD 33.9 million from AUD 36.2 million. Expenses were AUD 53.5 million, compared with AUD 53.7 million a year earlier, according to the company’s five-year financial summary.
Cash reserves increased to AUD 252.1 million at the end of FY26, from AUD 224.1 million in FY25. Total Assets were AUD 295.1 million, while total liabilities declined to AUD 22.2 million from AUD 30.9 million. Equity increased to AUD 272.9 million from AUD 240.8 million. The company reported AUD 39.6 million of Operating Cash Flow for FY26, versus AUD 41.1 million a year earlier.
The contrast between lower reported revenue and higher cash reserves illustrates why sales, Earnings and balance-sheet changes should be considered separately. Financial capacity may support ongoing research and commercial operations, but the costs, timing and outcomes of clinical and regulatory programmes remain distinct uncertainties.
Commercial and Clinical Risks
For Clinuvel (ASX:CUV), commercial access to an orphan-disease treatment is affected by prescribing practices, patient identification, reimbursement and local regulation. Development projects face clinical study, manufacturing, intellectual-property and approval risks. Foreign-market operations can also affect the timing of receipts and expenses.
What to Monitor
Subsequent releases may provide information on SCENESSE commercial activity, patient access and progress in development programmes. The next financial results will help show whether operating cash generation and product revenue follow the FY26 pattern. Regulatory outcomes should be interpreted according to the specific treatment and Jurisdiction involved.
The company’s financial summary records a net increase in cash reserves of AUD 27.9 million in FY26, compared with AUD 40.2 million in FY25. That annual change differs from operating cash flow because cash movements can also reflect investing and financing activities. Future reports can be assessed for both operating cash generation and the funding allocated to clinical development.
Key Insights
Clinuvel (ASX:CUV) remained profitable in FY26 and ended the year with higher cash reserves despite lower revenue and net profit. Its established EPP product and wider research portfolio have different operating profiles. Monitoring commercial sales, cash flows and independently reported clinical milestones remains important.





_11_19_2026_18_29_00_678569.jpg)
Please wait processing your request...